Paul Weiss

Neurovance, Inc. operates as a a biopharmaceutical company. It develops treatments for central nervous system disorders. The company was founded by Anthony McKinney and Franklin P. Bymaster in 2011 and is headquartered in Cambridge, MA.

Venture Investors LLC (Venture Investors) is a venture capital firm founded in 1984. The firm is headquartered in Madison, Wisconsin.

Part of Cardinal Health, Inc., Gala Biotech develops gene insertion technology to produce pharmaceutical proteins. The company is based in Middleton, WI. Gala Biotech was acquired by Cardinal Health, Inc. on October 01, 2003 for $15.50 million.

Scientific Protein Laboratories LLC supplies pharmaceutical ingredients. It specializes in cGMP biopharmaceutical manufacturing and commercial supplies. The firm serves the pharmaceutical, veterinary, and food industries. It offers fermentation, natural product extractions, heparin derivatives, and recovery and purification. The company founded in 1976 and is headquartered in Waunakee, WI.

Catalent Pharma Solutions, Inc. engages in the development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Development and Clinical Services, Oral Technologies, and Medication Delivery Solutions. The Development and Clinical Services segment manufactures, packs, stores distributes, and manages inventory for global clinical trials of drugs and biologics. The Oral Technologies segment formulates, develops, and manufactures prescription and consumer health products using various technologies. The Medication Delivery Solutions segment develops, formulates, and manufactures prefilled syringes and other injectable formats. The company was founded in 2002 and is headquartered in Somerset, NJ.

ProCertus BioPharm, Inc. operates as an oncology-based pharmaceutical company. Its product includes DermX, ProDermaCel, and OralX, proprietary pharmaceuticals which are designed to reduce or eliminate the side effects associated with cancer therapy. ProDermaCel will protect cancer patients from chemotherapy- and radiotherapy-induced alopecia (hair loss), DermX will prevent radiotherapy-induced dermatitis (skin burn), and OralX will protect against chemotherapy- and radiotherapy-induced oral mucositis. The company was founded by William E. Fahl and in 1997 and is headquartered in Madison, WI.

Tissue Regeneration Systems, Inc. is a medical device company commercializing a skeletal reconstruction and bone regeneration technology platform. Its platform has two novel and proprietary components, which include scaffold technology and coating technology. The company was founded by James R. Adox, Stephen E. Feinberg, William L. Murphy, Frank La Marca, and Scott Hollister in January 2005 and is headquartered in Plymouth, MI.

Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA.

Madison Vaccines, Inc. develops vaccines for patients with prostate cancer. It is also developing a sensitivity test to identify those patients who will derive clinical benefit from these vaccines. The firm develops immunological therapies in patients with minimal residual disease, and for whom the mechanism of action of vaccines is ideally suited. The company was founded by Richard R. Lesniewski and Douglas G. McNeel in 2012 and is headquartered in Madison, WI.

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH.

The University of Wisconsin Biotechnology Center provides core facilities for various biotechnology services such as bioinformatics, next-generation sequencing, genome editing, animal models, gene expression, mass spectrometry, and isotope ratio mass spectrometry. The center is based in Madison, WI. The center also offers outreach programs such as Biogarage and Biotrek. Payment instructions are included on the invoice for external customers.